Abstract

Anxiety disorders (AD) are the most common mental conditions affecting an estimated 40 million adults in the United States. Amiloride, a diuretic agent, has shown efficacy in reducing anxious responses in preclinical models by inhibiting the acid-sensing ion channels (ASIC). By delivering amiloride via nasal route, rapid onset of action can be achieved due to direct “nose-to-brain” access. Therefore, this study reports the formulation, physical, chemical, and microbiological stability of an extemporaneously prepared amiloride 2 mg/mL nasal spray. The amiloride nasal spray was prepared by adding 100 mg of amiloride hydrochloride to 50 mL of sterile water for injection in a sterile reagent bottle. A stability-indicating high-performance liquid chromatography (HPLC) method was developed and validated. Forced-degradation studies were performed to confirm the ability of the HPLC method to identify the degradation products from amiloride distinctively. The physical stability of the amiloride nasal spray was assessed by pH, clarity, and viscosity assessments. For chemical stability studies, samples of nasal sprays stored at room temperature were collected at time-points 0, 3 hr., 24 hr., and 7 days and were assayed in triplicate using the stability-indicating HPLC method. Microbiological stability of the nasal spray solution was evaluated for up to 7 days based on the sterility test outlined in United States Pharmacopoeia (USP) chapter 71. The stability-indicating HPLC method identified the degradation products of amiloride without interference from amiloride. All tested solutions retained over 90% of the initial amiloride concentration for the 7-day study period. There were no changes in color, pH, and viscosity in any sample. The nasal spray solutions were sterile for up to 7 days in all samples tested. An extemporaneously prepared nasal spray solution of amiloride hydrochloride (2 mg/mL) was physically, chemically, and microbiologically stable for 7 days when stored at room temperature.

Highlights

  • Anxiety disorders (AD) are the most common mental illnesses in every age group, affecting 25% of children and an estimated 40 million adults in the United States [1]

  • In a series of comparative human and preclinical studies of responses to CO2 [5,6,7,8,9,10], we reported that life adversities enhance the liability to anxiety and pain through the enrichment of acid-sensing ion channel (ASIC) genes -1 and -2 [11,12,13]

  • We report on the extemporaneous formulation of amiloride nasal spray and its physical, chemical, and microbiological stability

Read more

Summary

Introduction

Anxiety disorders (AD) are the most common mental illnesses in every age group, affecting 25% of children and an estimated 40 million adults in the United States [1]. Risk factors for developing AD include genetics, life adversities, and subtle brain chemistry alterations [1]. Pharmacological and cognitive-behavioral interventions, alone or in combination, are typically employed to treat AD [2, 3]. Contemporary first-line pharmacological agents for AD include selective serotonin reuptake inhibitors (SSRIs) and some serotonin noradrenalinereuptake inhibitors (SNRIs). SSRIs and SNRIs are better tolerated than older generation tricyclic antidepressants and show moderate-to-good effectiveness. The effectiveness and duration of treatment are not significantly different compared with tricyclic antidepressants, and many people experience relapse [4]. This highlights the unmet need for improved therapeutics in AD [2, 3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call